A Positive sign in this Industry? What's Cheaper your own shares or a hypothetical acquisition currently about 10x earnings. Heck buy em back, you can always issue more!
PORTSMOUTH, N.H.--(BUSINESS WIRE)--Oct. 21, 2002--Apogent Technologies Inc. ( NYSE: AOT), a leading manufacturer of laboratory and life science products, announced today expanded business guidance for its fiscal year 2003.
Reiterating its business guidance for the fiscal year ending September 30, 2003, Frank H. Jellinek, Jr., Apogent's President and Chief Executive Officer, stated, "Revenues for fiscal 2003 are expected to be approximately 8-10% higher than fiscal 2002. Operating margins are expected to be maintained or slightly enhanced as the year progresses, and our balance sheet is expected to grow even stronger. Our fully diluted earnings per share from continuing operations are projected to range from $1.37 to $1.44 for the year, a slight increase from prior guidance. This guidance does not reflect the benefits anticipated from additional purchases under our share buyback program (currently 50% complete at 1,000,000 shares purchased) or from any new acquisitions."
The quarterly pacing of the projected earnings per share range for fiscal 2003 is expected to be approximately as follows:
First Quarter $ 0.28-0.29 |
